论文部分内容阅读
目的观察缬沙坦治疗慢性心力衰竭的临床效果及安全性分析。方法选取医院收治的慢性心力衰竭患者60例,随机分为观察组和对照组,每组30例。对照组采用常规治疗法,观察组在对照组基础上给予缬沙坦治疗。观察2组患者慢性心力衰竭病情控制情况;治疗过程不良反应发生情况;治疗前后心功能、心率及血清学指标的差异。结果观察组慢性心力衰竭病情控制总有效率为96.67%,高于对照组的73.33%(P<0.05);治疗后,2组心功能、心率及血清学指标较治疗前均改善,且观察组各指标改善幅度更大(P均<0.05)。2组不良反应发生率比较差异无统计学意义(P>0.05)。结论缬沙坦治疗慢性心力衰竭的有效性与安全性高,可改善患者心功能、心率及血清学指标,无明显不良反应,病情控制效果好,值得推广应用。
Objective To observe the clinical efficacy and safety of valsartan in the treatment of chronic heart failure. Methods Sixty patients with chronic heart failure admitted to hospital were randomly divided into observation group and control group with 30 cases in each group. The control group was treated by conventional therapy. The observation group was treated with valsartan on the basis of the control group. Two groups of patients with chronic heart failure to observe the condition control; adverse reactions during the treatment; before and after treatment, heart function, heart rate and serological indicators differences. Results The total effective rate of chronic heart failure in observation group was 96.67%, which was higher than that in control group (73.33%, P <0.05). After treatment, heart function, heart rate and serological indexes of two groups were improved than before treatment, Each index improved more (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Valsartan is effective and safe in treating chronic heart failure. It can improve heart function, heart rate and serological indexes of patients with no obvious adverse reactions. The disease control effect is good and worth popularizing and applying.